RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase. The purpose of this
study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of
RX108 in patients with locally advanced or metastatic solid tumors.
Additional locations may be listed on ClinicalTrials.gov for NCT03646071.
See trial information on ClinicalTrials.gov for a list of participating sites.
This is a open-label, two-part study comprised of a dose escalation part and a dose
expansion part. In the dose escalation part, RX108 will be administered in ascending
doses to evaluate the safety and tolerability of RX108 and determine the maximum
tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). The dose expansion part will
assess the safety, pharmacokinetics, and efficacy of RX108 at the RP2D.
Lead OrganizationNeuPharma, Inc.
